ABCs in Dermatology: Getting to Know Your Hosts

The debut of ABCs in Dermatology sets the tone for a series grounded as much in clinical insight as in the human experience of care, with co-hosts Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, reflecting on the values that shape their approach to patients and the specialty itself. In this introductory exchange, the discussion moves beyond traditional clinical framing to emphasize the importance of perspective, gratitude, and authenticity in dermatologic practice. Ackerman highlights the role of gratitude as a foundational principle, describing dermatology not only as a scientific discipline but as a privilege—one that allows clinicians to meaningfully alter the trajectory of patients’ lives, particularly for those affected by stigmatizing or debilitating skin diseases. He underscores how advances in care can restore participation in daily life for patients who might otherwise be sidelined during critical developmental years . Bunick builds on this perspective by emphasizing the responsibility inherent in the physician–patient relationship, noting that clinical encounters extend beyond visible symptoms to encompass the broader, often unseen challenges patients carry. He points to the importance of empathy, humor, and intentional engagement, suggesting that even small moments of connection can have a lasting impact on patient outcomes and experience. Together, their reflections frame ABCs in Dermatology as a platform that will not only explore emerging science and clinical decision-making but also reinforce the interpersonal and ethical dimensions of care. The conversation establishes a clear throughline for the series: a commitment to authenticity, continuous learning, and a patient-centered mindset that recognizes the profound influence dermatology can have on both health and quality of life.

Relevant disclosures for Bunick include AbbVie, South Beach Symposium, Almirall, Apogee Therapeutics, Arcutis Biotherapeutics, Daiichi Sankyo, Eli Lilly, LEO Pharma, US, Novan, Novartis, Ortho Dermatologics, Palvella Therapeutics, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Timber Pharmaceuticals, and UCB. Relevant disclosures for Ackerman include AbbVie, Alumis, Amgen, Arcutis, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, L'Oréal, Novartis, Sun Pharmaceutical, and UCB.